NewAmsterdam Pharma Company N.V.
NASDAQ:NAMSBiotechnology
+$0.12 today
- Market cap
- $2.37B
- Beta
- 0.08
- P/E (TTM)
- -17.2
- EPS (TTM)
- -$1.76
Volume 1.80M
Average 1.21M
NAMS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
NewAmsterdam Pharma Company N.V.NASDAQ: NAMS
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of $80K (cash outflow) fell 9.1% year over year, behind the +42.9% change in trailing-twelve-month capital expenditures. Sequentially, it rose 110.5% from the prior quarter. Over 3 fiscal years it compounded at +3.6% a year.
Context
- Capital expenditures amounted to 1.1% of revenue in FY2025, down 0.4 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -9.1% toward the trailing-twelve-month pace of +42.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (246K) USD
- Year-over-year change
- +63.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (246K) | +63.4% |
| FY2024 | 2024-12-31 | (672K) | -2700.0% |
| FY2023 | 2023-12-31 | (24K) | +89.1% |
| FY2022 | 2022-12-31 | (221K) | -820.8% |
| FY2021 | 2021-12-31 | (24K) | — |
Capital Expenditures vs competitors
How NAMS compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +42.9% is the 4th highest of 8, against a peer median of -3.8%.
- Capital expenditures amounts to 3.7% of revenue for NAMS, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $8.57M USD | +779.8% | +29.1% | 0.7% | |
| LTM Jun 2026 | $3.42M USD | -81.4% | -18.9% | 94.8% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $1.02M USD | -3.8% | -26.2% | 1.1% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K USD | -59.7% | +91.1% | 3.1% |
| LTM Jun 2026 | $260K USD | +42.9% | +3.6% | 3.7% | |
| LTM Sep 2026 | $141K USD | +95.8% | -62.1% | — | |
| LTM Mar 2026 | $9K USD | -89.3% | -18.2% | — | |
| FY2025 | A$3 AUD | +100.1% | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| Peer median (excluding NAMS) | — | -3.8% | -18.6% | 1.1% | |
Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (41.79M) | (22.63M) | (176.94M) | (241.6M) | (203.82M) |
| Depreciation & Amortization | 5K | 9K | 49K | 113K | 220K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.24M | 4.12M | 24.57M | 33.62M | 59.43M |
| Change in Working Capital | 4.47M | 10.37M | 5.87M | (32.67M) | (7.94M) |
| Accounts Receivables | 0 | (4.18M) | 4.03M | 0 | (13.28M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 6.56M | 4.81M | 5.07M | (12.95M) | 4.91M |
| Other Working Capital | (2.09M) | 9.75M | (3.23M) | (19.73M) | 427K |
| Other Non-Cash Items | 6.55M | 18.8M | 5.23M | 81.98M | 4.34M |
| Operating Cash Flow | (29.51M) | 10.67M | (141.22M) | (158.56M) | (147.78M) |
| Capital Expenditures | (24K) | (221K) | (24K) | (672K) | (246K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (62.18M) | (296.73M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 122.06M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (24K) | (221K) | (24K) | (62.85M) | (174.92M) |
| Debt Repayment | 0 | 747K | 0 | 0 | 0 |
| Common Stock Issued | 84.7M | 396.95M | 8.91M | 645.51M | 29.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (5.79M) | 0 | 14M | 0 |
| Financing Cash Flow | 84.7M | 391.91M | 8.91M | 659.51M | 29.52M |
| Effect of Forex Changes | (4.68M) | 5.25M | 5.05M | (6.8M) | 12.76M |
| Net Change in Cash | 50.49M | 407.6M | (127.28M) | 431.29M | (280.42M) |
| Free Cash Flow | (29.54M) | 10.44M | (141.24M) | (159.24M) | (148.03M) |
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
Intrinsic Alpha fair value
Locked
Current Price
$19.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.